Pavinetant

From Wikipedia, the free encyclopedia
  (Redirected from MLE-4901)
Jump to navigation Jump to search
Pavinetant
MLE-4901.svg
Clinical data
SynonymsMLE-4901; AZD-4901; AZD-2624; AZ-12472520
Routes of
administration
By mouth
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
FormulaC26H25N3O3S
Molar mass459.564 g/mol g·mol−1
3D model (JSmol)

Pavinetant (INN, USAN; developmental code names MLE-4901, AZD-4901, AZ-12472520, AZD-2624), is a small-molecule, orally active, selective neurokinin-3 (NK3) receptor antagonist which was under development by AstraZeneca and Millendo Therapeutics for the treatment of hot flashes and polycystic ovary syndrome (PCOS).[1][2][3] It was also under investigation for the treatment of schizophrenia,[2] but development was discontinued for this indication due to lack of effectiveness.[1][4] In November 2017, development of the medication for hot flashes and PCOS was also terminated after its developer assessed the clinical risks and benefits.[1][3]

See also[edit]

References[edit]

  1. ^ a b c http://adisinsight.springer.com/drugs/800038259
  2. ^ a b Malherbe P, Ballard TM, Ratni H (2011). "Tachykinin neurokinin 3 receptor antagonists: a patent review (2005 - 2010)". Expert Opin Ther Pat. 21 (5): 637–55. doi:10.1517/13543776.2011.568482. PMID 21417773.
  3. ^ a b Sassarini J, Anderson RA (2017). "New pathways in the treatment for menopausal hot flushes". Lancet. doi:10.1016/S0140-6736(17)30886-3. PMID 28385351.
  4. ^ Litman RE, Smith MA, Desai DG, Simpson T, Sweitzer D, Kanes SJ (2014). "The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study". J Clin Psychopharmacol. 34 (2): 199–204. doi:10.1097/JCP.0000000000000071. PMID 24525659.

External links[edit]